The introduction of anti-TNF monoclonal antibody agents (infliximab and adalimumab) may constitute a major therapeutic advance in the treatment of BS; however, the effect on uveitis activity may be less convincing.BS is a chronic and progressive disease with a variable and often unpredictable spectrum of severity.